SCHEMBL855587

SCHEMBL855587

Nc1ncc(Br)cc1S(=O)(=O)NC1CCN(C(=O)O)CC1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.74
KDM4E B2RXH2 3/20 0.74
GFER P55789 2/20 0.48
ALDH1A1 P00352 4/20 0.47
GAA P10253 1/20 0.47
NPC1 O15118 1/20 0.44
LMNA P02545 4/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
PLA2G1B P04054 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
POLB P06746 1/20 0.41
SHMT2 P34897 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856749 0.93 HSD17B10 (0.68) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL856020 0.85 HSD17B10 (0.78) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL741358 0.85 HSD17B10 (0.64) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL855559 0.82 HSD17B10 (0.61) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL6118943 0.82 HSD17B10 (0.66) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL27868753 0.81 HSD17B10 (0.67) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL858797 0.81 HSD17B10 (0.69) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL856401 0.81 HSD17B10 (0.69) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL856400 0.81 HSD17B10 (0.69) HSD17B10KDM4EGFERALDH1A1GAA
SCHEMBL3764150 0.80 HSD17B10 (0.62) HSD17B10KDM4EGFERALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 1254/4885KDM4E 610/4885GFER 3964/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 711/4885KDM4E 361/4885GFER 4111/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 1066/4885KDM4E 760/4885GFER 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.